Effects of oral prajmaline bitartrate on exercise test responses in patients with coronary artery disease.
The safety, tolerability and haemodynamic effects of oral prajmaline bitartrate were assessed in a double-blind, randomized, placebo-controlled, crossover trial in 21 patients with stable angina pectoris and coronary artery disease. No serious side-effects occurred. Prajmaline bitartrate produced no statistically significant changes in resting heart rate or systolic blood pressure or in work capacity on the treadmill, or in heart rate or systolic blood pressure at maximum exercise compared to placebo values. No new arrhythmias or conduction abnormalities were produced in any patient. We conclude that oral prajmaline bitartrate is well tolerated and can be given safely to patients with coronary artery disease without producing deleterious haemodynamic effects or changes in exercise capacity.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000404:Ajmaline / Q000031:analogs & derivatives*; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology*; D005080:Exercise Test; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011219:Prajmaline / Q000009:adverse effects* / Q000097:blood
D000404:Ajmaline; D011219:Prajmaline